The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

In situations with more favorable market access contracts, Novavax is demonstrating the ability to compete with the mRNA ...

On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...

The newest case is the fifth to bring similar allegations against Moderna in the same court, with three others, all filed Nov ...

Public health experts are warning that the rising rates of RSV in the Southern U.S. could be a sign we need to prepare here in Southern California At one hospital in Texas, doctors are sounding the ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...